Allergan plc, a leading global pharmaceutical company, and its subsidiaries has announced that it has reached a settlement regarding its litigation with Famy Care Limited relating to Allergan's United States Patent Nos. 8,629,111; 8,633,162; 8,642,556; 8,648,048; 8,685,930 and 9,248,191 covering Restasis (Cyclosporine Ophthalmic Emulsion) 0.05%. The patents are listed in the Orange Book and expire on August 27, 2024.

As a result of the settlement, all Famy Care litigation regarding Restasis patents will be dismissed and Famy Care will terminate its pending petitions for Inter Parties Review. Allergan will grant Famy Care a license to market a generic version of Restasis in the United States beginning on February 27, 2024, or earlier under certain circumstances. Additional details regarding the settlement were not disclosed.